What is Lecanemab? Wiki, price, details, information, latest news and more
Lecanemab is a popular Japanese and American drug that is used to treat Alzheimer’s disease. Lecanemab is a humanized version of the mouse antibody mAb158 that locates protofibrils and prevents amyloid beta deposition in animal models of Alzheimer’s disease. Sep 27, 2022 Tokyo and Cambridge, Mass. PRNewswire/ — Eisai Co., Ltd., headquartered in Tokyo and CEO Haruo Naito, “Eisai” and Biogen Inc.
Nasdaq: BIIB, Cambridge, Mass.-headquartered company with CEO Michel Vounatsos, “Biogen” announced top results from Eisai’s large global confirmatory phase 3 clinical trial of Clarity AD with lecanemab. Lecanemab is an anti-amyloid beta (Aβ) protofibril antibody tested for the treatment of mild cognitive impairment (MCI). Which affects as a result of Alzheimer’s disease and mild AD with the confirmed presence of amyloid pathology in the brain.
Table of Contents
Lecanemab is Alzheimer’s treatment
The success of an experimental Alzheimer’s disease treatment is being hailed as a “historic moment” and a study shows why early-stage patients treated with lecanemab had 27% less decline than patients taking a placebo. Eisai is now looking to file for traditional approval in the United States, as well as submit applications for registration in Japan and Europe by the end of Eisai fy2022, which ends on March 31, 2023.
Treatment of Alzheimer’s disease with lecanemab
Lecanemab is a monoclonal antibody medicine and Lecanemab is a whole type of antibody. The source of lecanemab is humanized and the target is beta amyloid. Lecanemab’s scientific name is BAN2401 and the ATC code is none. The legal status of Lecanemab is Investigational and the CAS number is 1260393-98-3 and the DrugBank number is DB14580. Lecanemab’s ChemSpider is still being updated. The UNII number of Lecanemab is 12PYH0FTU9 and the KEGG number is D11678.
All key secondary endpoints of Lecanemab were also met, demonstrating highly statistically significant results, and the incidence profile of amyloid-related imaging abnormalities (Aria) was within expectations. According to reports, Lecanemab is very effective against Alzheimer’s disease.
More Information About Lecanemab In Video